BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

829 related articles for article (PubMed ID: 26264609)

  • 21. Sustained Tumor Control With MAPK Inhibition in
    Berzero G; Bellu L; Baldini C; Ducray F; Guyon D; Eoli M; Silvani A; Dehais C; Idbaih A; Younan N; Nguyen-Them L; Gaillard S; Pasqualetti F; Lepage-Seydoux C; Sekkate S; Tresca P; Kas A; Gratieux J; Ammari S; Saragoussi E; Savatovsky J; Delattre JY; Hoang-Xuan K; Meyronet D; Villa C; Bielle F; Sanson M; Touat M; Di Stefano AL
    Neurology; 2021 Aug; 97(7):e673-e683. PubMed ID: 34088874
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pediatric low-grade gliomas can be molecularly stratified for risk.
    Yang RR; Aibaidula A; Wang WW; Chan AK; Shi ZF; Zhang ZY; Chan DTM; Poon WS; Liu XZ; Li WC; Zhang RQ; Li YX; Chung NY; Chen H; Wu J; Zhou L; Li KK; Ng HK
    Acta Neuropathol; 2018 Oct; 136(4):641-655. PubMed ID: 29948154
    [TBL] [Abstract][Full Text] [Related]  

  • 23. BRAF V600E-mutated diffuse glioma in an adult patient: a case report and review.
    Suzuki Y; Takahashi-Fujigasaki J; Akasaki Y; Matsushima S; Mori R; Karagiozov K; Joki T; Ikeuchi S; Ikegami M; Manome Y; Murayama Y
    Brain Tumor Pathol; 2016 Jan; 33(1):40-9. PubMed ID: 26445861
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dysembryoplastic neuroepithelial tumors share with pleomorphic xanthoastrocytomas and gangliogliomas BRAF(V600E) mutation and expression.
    Chappé C; Padovani L; Scavarda D; Forest F; Nanni-Metellus I; Loundou A; Mercurio S; Fina F; Lena G; Colin C; Figarella-Branger D
    Brain Pathol; 2013 Sep; 23(5):574-83. PubMed ID: 23442159
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Co-occurrence of histone H3 K27M and BRAF V600E mutations in paediatric midline grade I ganglioglioma.
    Pagès M; Beccaria K; Boddaert N; Saffroy R; Besnard A; Castel D; Fina F; Barets D; Barret E; Lacroix L; Bielle F; Andreiuolo F; Tauziède-Espariat A; Figarella-Branger D; Puget S; Grill J; Chrétien F; Varlet P
    Brain Pathol; 2018 Jan; 28(1):103-111. PubMed ID: 27984673
    [TBL] [Abstract][Full Text] [Related]  

  • 26. BRAF-mutated pleomorphic xanthoastrocytoma is associated with temporal location, reticulin fiber deposition and CD34 expression.
    Koelsche C; Sahm F; Wöhrer A; Jeibmann A; Schittenhelm J; Kohlhof P; Preusser M; Romeike B; Dohmen-Scheufler H; Hartmann C; Mittelbronn M; Becker A; von Deimling A; Capper D
    Brain Pathol; 2014 Apr; 24(3):221-9. PubMed ID: 24345274
    [TBL] [Abstract][Full Text] [Related]  

  • 27. PD-L1 Expression in Pediatric Low-Grade Gliomas Is Independent of BRAF V600E Mutational Status.
    Martin AM; Bell WR; Yuan M; Harris L; Poore B; Arnold A; Engle EL; Asnaghi L; Lim M; Raabe EH; Eberhart CG
    J Neuropathol Exp Neurol; 2020 Jan; 79(1):74-85. PubMed ID: 31819973
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Morphological and molecular features of astroblastoma, including BRAFV600E mutations, suggest an ontological relationship to other cortical-based gliomas of children and young adults.
    Lehman NL; Hattab EM; Mobley BC; Usubalieva A; Schniederjan MJ; McLendon RE; Paulus W; Rushing EJ; Georgescu MM; Couce M; Dulai MS; Cohen ML; Pierson CR; Raisanen JM; Martin SE; Lehman TD; Lipp ES; Bonnin JM; Al-Abbadi MA; Kenworthy K; Zhao K; Mohamed N; Zhang G; Zhao W
    Neuro Oncol; 2017 Jan; 19(1):31-42. PubMed ID: 27416954
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prevalence of BRAFV600 in glioma and use of BRAF Inhibitors in patients with BRAFV600 mutation-positive glioma: systematic review.
    Andrews LJ; Thornton ZA; Saincher SS; Yao IY; Dawson S; McGuinness LA; Jones HE; Jefferies S; Short SC; Cheng HY; McAleenan A; Higgins JPT; Kurian KM
    Neuro Oncol; 2022 Apr; 24(4):528-540. PubMed ID: 34718782
    [TBL] [Abstract][Full Text] [Related]  

  • 30. MRI characteristics predict BRAF V600E status in gangliogliomas and pleomorphic xanthoastrocytomas and provide survival prognostication.
    Jiang B; Zheng Y; She D; Xing Z; Cao D
    Acta Radiol; 2024 Jan; 65(1):33-40. PubMed ID: 37401109
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and Safety of Dabrafenib in Pediatric Patients with
    Hargrave DR; Bouffet E; Tabori U; Broniscer A; Cohen KJ; Hansford JR; Geoerger B; Hingorani P; Dunkel IJ; Russo MW; Tseng L; Dasgupta K; Gasal E; Whitlock JA; Kieran MW
    Clin Cancer Res; 2019 Dec; 25(24):7303-7311. PubMed ID: 31811016
    [TBL] [Abstract][Full Text] [Related]  

  • 32. MR Imaging of Pediatric Low-Grade Gliomas: Pretherapeutic Differentiation of
    Trasolini A; Erker C; Cheng S; Crowell C; McFadden K; Moineddin R; Sargent MA; Mata-Mbemba D
    AJNR Am J Neuroradiol; 2022 Aug; 43(8):1196-1201. PubMed ID: 35863783
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Surgical and molecular considerations in the treatment of pediatric thalamopeduncular tumors.
    Lee RP; Foster KA; Lillard JC; Klimo P; Ellison DW; Orr B; Boop FA
    J Neurosurg Pediatr; 2017 Sep; 20(3):247-255. PubMed ID: 28686121
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The differential diagnosis of pilocytic astrocytoma with atypical features and malignant glioma: an analysis of 16 cases with emphasis on distinguishing molecular features.
    Cykowski MD; Allen RA; Kanaly AC; Fung KM; Marshall R; Perry A; Stolzenberg ED; Dunn ST
    J Neurooncol; 2013 Dec; 115(3):477-86. PubMed ID: 24057326
    [TBL] [Abstract][Full Text] [Related]  

  • 35. T2-FLAIR Mismatch Sign in Pediatric Low-Grade Glioma.
    Wagner MW; Nobre L; Namdar K; Khalvati F; Tabori U; Hawkins C; Ertl-Wagner BB
    AJNR Am J Neuroradiol; 2023 Jul; 44(7):841-845. PubMed ID: 37348970
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Association of molecular alterations, including BRAF, with biology and outcome in pilocytic astrocytomas.
    Horbinski C; Hamilton RL; Nikiforov Y; Pollack IF
    Acta Neuropathol; 2010 May; 119(5):641-9. PubMed ID: 20044755
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Molecular characterization of disseminated pilocytic astrocytomas.
    Gessi M; Engels AC; Lambert S; Rothämel T; von Hornstein S; Collins VP; Denkhaus D; Gnekow A; Pietsch T
    Neuropathol Appl Neurobiol; 2016 Apr; 42(3):273-8. PubMed ID: 26084390
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase II Weekly Vinblastine for Chemotherapy-Naïve Children With Progressive Low-Grade Glioma: A Canadian Pediatric Brain Tumor Consortium Study.
    Lassaletta A; Scheinemann K; Zelcer SM; Hukin J; Wilson BA; Jabado N; Carret AS; Lafay-Cousin L; Larouche V; Hawkins CE; Pond GR; Poskitt K; Keene D; Johnston DL; Eisenstat DD; Krishnatry R; Mistry M; Arnoldo A; Ramaswamy V; Huang A; Bartels U; Tabori U; Bouffet E
    J Clin Oncol; 2016 Oct; 34(29):3537-3543. PubMed ID: 27573663
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Diencephalic pediatric low-grade glioma harboring the BRAF V600E mutation presenting with various morphologies in sequential biopsy specimens.
    Ishi Y; Hatanaka KC; Yamaguchi S; Fujita H; Motegi H; Kobayashi H; Terasaka S; Houkin K
    Brain Tumor Pathol; 2017 Oct; 34(4):165-171. PubMed ID: 28836232
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Epithelioid GBMs show a high percentage of BRAF V600E mutation.
    Kleinschmidt-DeMasters BK; Aisner DL; Birks DK; Foreman NK
    Am J Surg Pathol; 2013 May; 37(5):685-98. PubMed ID: 23552385
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 42.